A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114, in combination with irinotecan in patients with advanced cancer.

被引:0
|
作者
Eckhardt, SG
Kuhn, JG
Britten, CD
Weitman, S
Baker, SD
MacDonald, JR
Newman, A
Smith, S
Von Hoff, DD
Rowinsky, EK
机构
[1] MGI PHARMA, Minnetonka, MN USA
[2] Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
319
引用
收藏
页码:3793S / 3793S
页数:1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Schellens, JH
    Rademaker, JL
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Reijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Beijnen, JH
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3694S - 3694S
  • [32] Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.
    Beijnen, JH
    Rademaker-Lakhai, JM
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Rijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 146S - 146S
  • [33] Phase II study of combination chemotherapy using irinotecan and nedaplatin for patients with primary advanced or recurrent cervical cancer.
    Ohwada, M
    Machida, S
    Fujiwara, H
    Konno, R
    Takano, M
    Kita, T
    Kikuchi, Y
    Komiyama, S
    Mikami, M
    Suzuki, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 471S - 471S
  • [34] Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study.
    Creaven, PJ
    Javle, MM
    Pendyala, L
    Smith, P
    Noel, DC
    Iyer, RV
    Lawrence, DD
    Rustum, YM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 157S - 157S
  • [35] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [36] A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Rowinsky, Eric K.
    Beeram, Muralidhar
    Hammond, Lisa A.
    Schwartz, Garry
    De Bono, Johann
    Forouzesh, Baharam
    Chu, Quincy
    Latz, Jane E.
    Hong, Shengyan
    John, William
    Nguyen, Binh
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 532 - 539
  • [37] Phase I study of irinotecan (CPT-11) and capecitabine in combination with concurrent radiotherapy for locally advanced rectal cancer.
    Hofheinz, R
    Von Gerstenberg, B
    Wenz, F
    Gnad-Vogt, U
    Tiefenbacher, U
    Saussele, S
    Kreil, S
    Hochhaus, A
    Willeke, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 293S - 293S
  • [38] Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer
    Kasai, T
    Oka, M
    Soda, H
    Tsurutani, J
    Fukuda, M
    Nakamura, Y
    Kawabata, S
    Nakatomi, K
    Nagashima, S
    Takatani, H
    Fukuda, M
    Kinoshita, A
    Kohno, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (14) : 1871 - 1878
  • [39] Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC).
    Chau, I
    Massey, A
    Higgins, L
    Botwood, N
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 263S - 263S
  • [40] Phase I study of paclitaxel plus irinotecan combination therapy for patients with refractory and advanced gastric cancer
    Kobayashi, T.
    Sakagami, T.
    Koizuka, H.
    Yamamoto, N.
    Sasaki, T.
    Maeda, Y.
    Omuro, Y.
    Okamoto, R.
    Mikoshiba, M.
    Sasaki, E.
    Matsumoto, T.
    Miwa, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 : 266 - 271